# Accendra Health Inc: overview

ACH · NYSE · CIK 75252 · [Consumer discretionary](/sectors/consumer-discretionary.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ach.md) · [Financials](/companies/ach/financials.md) · [Filings](/companies/ach/filings.md) · [Insiders](/companies/ach/insiders.md)

Latest reported revenue: [$613.2m](/filings/0001104659-26-093177.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 10, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-093177).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [687](/filings/0001104659-25-104506.md) | [695 d](/filings/0001104659-26-018169.md) | [674](/filings/0001104659-26-058465.md) | [682](/filings/0001104659-26-093177.md) | [697](/filings/0001104659-25-104506.md) | [709 d](/filings/0001104659-26-018169.md) | [628](/filings/0001104659-26-058465.md) | [613](/filings/0001104659-26-093177.md) |
| Gross margin | % | [81.5%](/filings/0001558370-24-014255.md) | [83.4% d](/filings/0001558370-25-001940.md) | [78.1%](/filings/0001558370-25-006964.md) | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [4.5%](/filings/0001104659-25-104506.md) | [(39.2%) d](/filings/0001104659-26-018169.md) | [2.9%](/filings/0001104659-26-058465.md) | [(5.8%)](/filings/0001104659-26-093177.md) | [3.8%](/filings/0001104659-25-104506.md) | [2.9% d](/filings/0001104659-26-018169.md) | [2.7%](/filings/0001104659-26-058465.md) | [(5.7%)](/filings/0001104659-26-093177.md) |
| Net margin | % | [(1.9%)](/filings/0001104659-25-104506.md) | [(42.6%) d](/filings/0001104659-26-018169.md) | [(3.7%)](/filings/0001104659-26-093177.md) | [(127.4%)](/filings/0001104659-26-093177.md) | [(21.6%)](/filings/0001104659-25-104506.md) | [(7.9%) d](/filings/0001104659-26-018169.md) | [(1.0%)](/filings/0001104659-26-093177.md) | [(14.5%)](/filings/0001104659-26-093177.md) |
| Diluted EPS | $ per share | [(0.16)](/filings/0001104659-25-104506.md) | not reported | [(0.32)](/filings/0001104659-26-058465.md) | [(11.30)](/filings/0001104659-26-093177.md) | [(1.94)](/filings/0001104659-25-104506.md) | not reported | [(0.08)](/filings/0001104659-26-058465.md) | [(1.16)](/filings/0001104659-26-093177.md) |
| Free cash flow | $m | [(34.2) d](/filings/0001104659-25-104506.md) | [48.7 d](/filings/0001558370-25-001940.md) | [(80.9)](/filings/0001558370-25-006964.md) | [(20.0) d](/filings/0001558370-25-011059.md) | [(247) d](/filings/0001104659-25-104506.md) | [55.1 d](/filings/0001104659-26-018169.md) | [(91.7)](/filings/0001104659-26-058465.md) | [(73.6) d](/filings/0001104659-26-093177.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [9,785](/filings/0001558370-24-001369.md) | [9,955](/filings/0001558370-25-001940.md) | [2,553](/filings/0001104659-26-018169.md) | [2,680](/filings/0001104659-26-018169.md) | [2,762](/filings/0001104659-26-018169.md) |
| Gross margin | % | [15.5%](/filings/0001558370-24-001369.md) | [18.3%](/filings/0001558370-25-001940.md) | [83.3%](/filings/0001558370-25-001940.md) | [82.8%](/filings/0001558370-25-001940.md) | not reported |
| Operating margin | % | [3.8%](/filings/0001558370-24-001369.md) | [1.4%](/filings/0001558370-25-001940.md) | [5.2%](/filings/0001104659-26-018169.md) | [(8.1%)](/filings/0001104659-26-018169.md) | [1.0%](/filings/0001104659-26-018169.md) |
| Net margin | % | [2.3%](/filings/0001558370-24-001369.md) | [0.2%](/filings/0001558370-25-001940.md) | [(1.6%)](/filings/0001104659-26-018169.md) | [(13.5%)](/filings/0001104659-26-018169.md) | [(39.8%)](/filings/0001104659-26-018169.md) |
| Diluted EPS | $ per share | [2.94](/filings/0001558370-24-001369.md) | [0.29](/filings/0001558370-25-001940.md) | [(0.53)](/filings/0001104659-26-018169.md) | [(4.73)](/filings/0001104659-26-018169.md) | [(14.31)](/filings/0001104659-26-018169.md) |
| Free cash flow | $m | [83.2](/filings/0001558370-24-001369.md) | [167](/filings/0001558370-25-001940.md) | [568](/filings/0001558370-25-001940.md) | [(8.8)](/filings/0001558370-25-001940.md) | [(293)](/filings/0001104659-26-018169.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment; Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/ach/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [Coliseum Capital Management, LLC](/funds/1409751.md) | 2026-06-30 | $44.8m | 13,100,807 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $18.8m | 5,504,102 |  | Added +268,802 |
| [BANK OF AMERICA CORP /DE/](/funds/70858.md) | 2026-06-30 | $12.9m | 3,775,525 |  | Added +368,450 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $10.6m | 3,087,931 |  | Reduced −194,243 |
| [D. E. Shaw & Co., Inc.](/funds/1009207.md) | 2026-06-30 | $10.5m | 3,081,407 |  | Reduced −230,194 |
| [CHARLES SCHWAB INVESTMENT MANAGEMENT INC](/funds/884546.md) | 2026-06-30 | $9.9m | 2,888,058 |  | Reduced −747,468 |
| [Invenomic Capital Management LP](/funds/1769456.md) | 2026-06-30 | $9.6m | 2,812,474 |  | Reduced −556,501 |
| [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $8.8m | 2,582,579 |  | Added +821,575 |
| [PARADIGM CAPITAL MANAGEMENT INC/NY](/funds/1037792.md) | 2026-06-30 | $8.7m | 2,536,699 |  | Added +750,299 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $6.9m | 2,030,956 |  | Reduced −620,196 |

## Recent filings

[All 2,043 filings](/companies/ach/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-29 | 16:15 ET | [DEF 14A](/filings/0001104659-26-120208.md) | Proxy statement, period 2026-12-01 | 0001104659-26-120208 |
| 2026-10-09 | 16:10 ET | [8-K](/filings/0001104659-26-115043.md) | 3.01 Delisting notice; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-115043 |
| 2026-09-28 | 17:06 ET | [8-K/A](/filings/0001104659-26-111408.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001104659-26-111408 |
| 2026-09-17 | 06:35 ET | [8-K](/filings/0001104659-26-108405.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-108405 |
| 2026-08-17 | 06:42 ET | [8-K](/filings/0001104659-26-097517.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-097517 |
| 2026-08-10 | 16:15 ET | [8-K](/filings/0001104659-26-093381.md) | 1.01 Entry into a material agreement; 3.03 Change to security holders’ rights; 5.03 Amendment to articles or bylaws; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-093381 |
| 2026-08-10 | 11:15 ET | [10-Q](/filings/0001104659-26-093177.md) | Quarterly report, period 2026-06-30 | 0001104659-26-093177 |
| 2026-08-10 | 06:50 ET | [8-K](/filings/0001104659-26-092999.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-092999 |
| 2026-08-10 | 06:36 ET | [8-K](/filings/0001104659-26-092973.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001104659-26-092973 |
| 2026-06-25 | 16:15 ET | [8-K](/filings/0001193125-26-282808.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-282808 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-018169.md), filed Feb 20, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/9ba0d281-7381-460c-82f4-207e49920cf4)

## About the filer

- CIK: 75252
- Tickers: ACH
- Exchange: NYSE
- SIC code: 5047 Wholesale-Medical, Dental & Hospital Equipment & Supplies
- State of incorporation: VA
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 16:18 ET. No prices; not investment advice.